Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|5|2|171-181

ISSN： 1574-8863

Source： Current Drug Safety, Vol.5, Iss.2, 2010-04, pp. : 171-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thrombopoiesis‐stimulating agents and myelodysplastic syndromes

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 309-323

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of Intravenous Immunoglobulin Treatment on Thrombopoiesis

By  

Transfusion Medicine and Hemotherapy, Vol. 39, Iss. 3, 2012-05 ,pp. : 217-220

Karger

Access to resources Recommend Favorite

Is There a Role for Low-Dose Eltrombopag as Maintenance Therapy in the Treatment of Immune Thrombocytopenia?

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 78-82

Karger

Access to resources Recommend Favorite

Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 215-228

Karger

Access to resources Recommend Favorite

Cyclosporine A in the Treatment of a Patient with Immune Thrombocytopenia Accompanied by Myelodysplastic Syndrome and Nephrotic Syndrome

By  

Acta Haematologica, Vol. 110, Iss. 1, 2003-09 ,pp. : 36-40

Karger

Access to resources Recommend Favorite